Trial Profile
A Phase 2, Single-Blind, Exploratory, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Daily Oral NYX-2925 in Subjects With Fibromyalgia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs NYX 2925 (Primary)
- Indications Fibromyalgia
- Focus Biomarker; Pharmacodynamics
- Sponsors Aptinyx
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 28 Oct 2019 Results published in the Aptinyx media release
- 28 Oct 2019 According to an Aptinyx media release, data from this study has been selected as a late-breaking poster presentation at the American College of Rheumatology Annual Meeting. ePoster to be presented at ACR Annual Meeting on Tuesday, November 12